MedWatch

Orphazyme-founder on IPO: Now we can take the company all the way

According to co-founder and CEO in Orphazyme, Anders Hinsby, an IPO gives the Danish biotech company a chance to take its products through the last development phase towards a drug approval.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

GSK får FDA nik til potentiel revolutionerende HIV-behandling

GSK har fået grønt lys fra de amerikanske lægemyndigheder, FDA, til selskabets mest lovende HIV-middel. Tilladelsen kan være indledningen til et paradigmeskifte inden for HIV-behandling, idet behandlingen reducerer antallet af lægemidler, patienterne behøver at tage.

Latest Top picks in English

Related articles